Tomorrow's Science For Today's Clinician
The AZD7442 PROVENT trial was the first Phase III trial prospectively designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic COVID-19, with targeted inclusion of high-risk and immunocompromised participants.
The trial led by a team of researchers at Haiphong University of Medicine and Pharmacy in Vietnam observed that the rates of bacterial eradication were higher in patients on the combination therapy than in those given single-antibiotic treatment (96.7% vs. 88.6%).
Wound infections are the most common problem after surgery, particularly in developing countries, but promised innovations to tackle the issue do not work and global guidance needs changing, a new study reveals.
Currently, there are a total of four Indian manufacturers, including Pune-based Serum Institute of India, Hyderababd-based Bharat Biotech and Dr Reddy’s Laboratories, and Ahmedabad-based Zydus Cadila, supplying Covid-19 vaccine in the country.
Clinical data and insight solutions enable pharmaceutical organisations such as ours to gain in-depth visibility into the patient’s journey by extracting actionable insights from disparate data sources. The establishment of the CDI division in India is key to our strategic vision of being industry leaders in this space.
In the study, the NIRTH team tested Gazelle to compare its accuracy against the standard laboratory tests, HPLC and hemoglobin electrophoresis. The results showed Gazelle performing with similar accuracy, but with more speed and ease.
Following the Committee recommendation, the Drug Controller General of India is soon expected to approve the vaccine for inclusion in the ongoing vaccination drive. The dosage of Covaxin in children is also fixed as two shots with a gap of 28 days.
In this newly created role, Pyke will lead and direct the operational execution and development of all facets of Parexel’s patient data strategy to differentiate the company as an industry leader in patient data insights.
Trial participants lived for a median of nearly one year after their therapy which is significant in comparison to previous benefits seen from chemotherapy alone
It has completed preclinical studies and animal tests, which have shown significant relief of symptoms and damage caused by novel coronavirus infection, and will enter phase III soon.